Showing posts with label Pleural. Show all posts
Showing posts with label Pleural. Show all posts

Friday, June 14, 2013

Pleural mesothelioma


A rare form of cancer caused by asbestos exposure. Pleural mesothelioma refers to cancer of the outer lining of the lung and chest cavity (called the “pleura”). It is the most common form of mesothelioma and accounts for approximately 70% of all mesothelioma diagnoses.

Pleural mesothelioma Symptoms
The most common symptoms of pleural mesothelioma are difficulty in breathing and pain in the lower back or chest, which are typically caused by pleural effusion (see below Fig 1)
. Other less common symptoms include weight loss, fever, fatigue, trouble swallowing, night sweats, cough, and a general feeling of not being well. Occasionally, a patient may not have symptoms at diagnosis.
Please keep in mind that these symptoms may be caused by mesothelioma or by other less serious conditions. Only a doctor, or preferably a mesothelioma specialist can make a definitive diagnosis.


FIG 1
Pleural effusion, is an accumulation of fluid between the parietal pleura (the pleura covering the chest wall and diaphragm) and the visceral pleura (the pleura covering the lungs). Both of these pleural membranes are comprised of mesothelial cells which, under normal circumstances, produces fluid that acts as a lubricant between the lung and the chest wall. Normally, any excess fluid is absorbed back into the system via the lymph vessels and blood. However, when too much builds up and cannot be drained, the result is an effusion. Pleural effusion is broken down into two categories, transudates and exudates. A transudate is a clear fluid that builds up not because the pleura itself is diseased, but rather because of an imbalance between fluid production and removal. An exudate, which is often times a cloudy fluid, results from disease of the pleura and is common to mesothelioma. In order to discover whether the fluid of the effusion is transudate or exudate, a fluid sample must be taken and analyzed.

Diagnosis
It can be difficult to diagnose mesothelioma because many of the mesothelioma symptoms are similar to those of a number of other conditions, including lung cancer and other types of cancers.

If mesothelioma is suspected, a doctor will typically do a physical examination and ask the patient for a complete a medical history which will include the possibility of prior exposure to asbestos. At this point, the most effective way to make a positive pleural mesothelioma diagnosis is for a mesothelioma specialist to examine tissue from the lung or tumor via a thoracoscopy, a mediastinoscopy or a bronchoscopy. There are several additional tests that can be used to assist in confirming the diagnosis of pleural mesothelioma, including a chest x-ray, CT scan, MRI scan, PET scan and examining the pleural fluid.

Thoracoscopy
In this procedure, a small incision is made in the chest and a thoracoscope, which is an instrument similar to a telescope and is connected to a video camera, is inserted in the area of the tumor. A doctor can then view the tumor and/or take a tissue (called a biopsy) at this time.

Mediastinoscopy
In a mediastinoscopy, a small incision is made just above the sternum and a lighted tube is placed behind the breast bone. allowing the doctor to view the lymph nodes which can provide clues about the body’s immune system, a tissue sample may be removed at this time. Once removed, the tissue samples are then analyzed under a microscope.

Bronchoscopy
In this procedure, a lighted tube is inserted through the mouth , down the throat and into the bronchi. Abnormal masses or irregular tissue can then be removed (called a biopsy) for testing.

Chest X-Ray
X-ray machines use radiation to take a picture of the lungs or affected area. An x-ray may reveal several types of abnormalities including buildup of fluid in the pleural space, irregular thickening of the pleura and pleural calcifications (mineral deposits). These abnormalities may indicate asbestos exposure and the development of mesothelioma.

Computed Tomography Scan Or CT Scan
Type of x-ray procedure that produces detailed cross-sectional images of the body. Unlike a traditional x-ray that takes a single picture, a CT scanner takes a series of pictures as it rotates around you. A computer then combines these images to create a cross-sectional “slice” of the body. A radiocontrast agent or “dye” may be injected into patient intravenously, which helps define the structures of the body and may help in determining the extent to which the cancer has spread.

Magnetic Resonance Imaging Or MRI
This scan uses radio waves, strong mangnets and a computer to produce a cross-sectional image of the body. The energy from the radio waves and magnets are absorbed and released by the different tissues in the body. In this procedure the patient may be injected with a radiocontrast agent prior to being positioned in the tunnel of the MRI machine.

Positron Emission Tomography  Scan
This scan uses radioactive glucose (sugar) to determine the spread of cancer. Cancer tissue consumes glucose at a much faster rate than normal tissue. When radioactive glucose is injected intervenously into the patient the diseased tissue takes up higher levels of the radioactive material and when scanned, can provide insight into the stage and spread of the cancer.


View the original article here

Wednesday, June 5, 2013

PLEURAL CANCER

Mesothelioma: PLEURAL CANCERskip to main | skip to sidebarMesotheliomaMesothelioma information, mesothelium, mesothelioma symptoms, mesothelioma prognosis

PagesHome PLEURAL CANCERPLEURAL CANCER OR
MESOTHELIOMA

Cancer or mesothelioma of the pleura is rare, but in the spotlight as its main cause is exposure to asbestos.

All about cancer or mesothelioma of the pleura

This is a cancer of the envelope of serious lung, which appears only late and for which there are limited treatment options.
PLEURAL CANCER
What causes cancer or mesothelioma of the pleura?

Cancer or mesothelioma of the pleura:
when to see?
Cancer or mesothelioma of the pleura:
What's going on there during the examination?
Cancer pleural mesothelioma or what is the treatment?
Newer PostOlder PostHomeSearchFollowersBlog Archive? 2012(30)? April(26)Cancer compensationMalignant cancersAsbestos exposure and cancerConsequences of cancer MesotheliomaCancer unknown primaryBenign mesothelioma of the uterusBenign MesotheliomaDiagnosis mesotheliomaWhat is asbestosDefine mesotheliomaPulmonary lobectomyALIMTAOncolytic virusesCancer fighting virusCancer glossaryPulmonary pleurisyFactors that increase the risk of cancerMesothelioma of the pleuraPLEURAL CANCERSkin cancer in young adultsOccupational disease workers compensationOccupational diseasesEmployer ResponsibilitiesOccupational healthcareWhat is pneumoconiosisOccupational cancer ?  March(2) ?  February(2) ?  2011(14) ?  December(9) ?  May(5)Popular PostsTreatment MesotheliomaTreatment Mesothelioma Most successful mesothelioma treatment methodology up to now After the diagnosis of mesothelioma cancer therapies...Alternative Treatments for MesotheliomaAlternative Treatments for Mesothelioma Natural Treatments Intended For Mesothelioma Cancer Mesothelioma , lung cancer can be determined ...Peritoneal Mesothelioma Cancer Peritoneal Mesothelioma Cancer Summary of treatment of Mesothelioma After the diagnosis of mesothelioma cancer the standard treatment is ...Mesomark Blood TestMesomark Blood Test Mesothelioma - Blood Test for Cancer Diagnosis Evidence so far in our measurements suggest that the serum SMRPs can ...Cancer in Abdominal CavityCancer in Abdominal Cavity Mesothelioma affects the body cavity Mesothelioma is a cancer of the mesothelium , which is the membrane that... Copyright © Mesothelioma

View the original article here

Thursday, May 30, 2013

The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos

Main Category: Asbestos / Mesothelioma
Article Date: 19 Mar 2012 - 0:00 PST Current ratings for:
The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos
not yet rated4 stars
Patients with early stage malignant pleural mesothelioma (MPM), a cancer that develops in the lining of the lungs, may be eligible for aggressive multi-modality therapy involving surgery, radiotherapy and chemotherapy. There are two main approaches, and controversy has existed about which approach is superior. One is called extrapleural pnemonectomy (EPP), a very extensive surgery where surgeons remove the entire diseased lung, lung lining (pleura), part of the membrane covering the heart (pericardium) and part of the diaphragm. Another approach involves a less extensive surgery called pleurectomy/decortication (P/D), where surgeons remove part of the lining around the lungs, potentially part, but not all of the lung, and potentially part of the diaphragm and/or membrane around the heart. Research presented in the April 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology concludes that the P/D method had better results for patients in a recent analysis.

According to the study, "EPP resulted in higher mortality and morbidity than P/D, and P/D resulted in significantly better survival in our experience as in others." The authors, "propose that P/D becomes the standard surgical procedure offered as part of multi-modality therapy in malignant pleural mesothelioma."

Until recently, EPP was the considered the standard of treatment. But this latest study along with other recent research seems to point to P/D becoming the new standard of treatment. Dr. Michael Weyant, thoracic surgeon and assistant professor at the University of Colorado, wrote an editorial in the April JTO about this topic. He concludes that, "the results of the current study by Lang-Lazdunksi et al provide additional data that should lead us to consider P/D in all trials of treatment for MPM. It is too early based on this data to completely abandon EPP altogether as there may be patient subsets where the potential reward outweighs the risks of the procedure."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our asbestos / mesothelioma section for the latest news on this subject. The lead author of this work is Dr. Loïc Lang-Lazdunski, IASLC member co-authors include Dr. David Landau and Dr. James Spicer, all at King's College London-Division of Cancer Studies.
International Association for the Study of Lung Cancer Please use one of the following formats to cite this article in your essay, paper or report:

MLA

International Association for the Study of Lung Ca. "The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos." Medical News Today. MediLexicon, Intl., 19 Mar. 2012. Web.
29 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'The Latest On Malignant Pleural Mesothelioma Caused By Exposure To Asbestos'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Wednesday, May 29, 2013

First Analysis Of IASLC Malignant Pleural Mesothelioma Database

Main Category: Asbestos / Mesothelioma
Article Date: 17 Oct 2012 - 1:00 PST Current ratings for:
First Analysis Of IASLC Malignant Pleural Mesothelioma Database
not yet ratednot yet rated
The International Mesothelioma Interest Group (IMIG) staging system has been widely used, however, widespread concerns exist about the validity of the current malignant pleural mesothelioma (MPM) staging system. Concerns include that the system is derived from analysis of small, retrospective surgical series; it can be difficult to apply to clinical staging; and uses descriptors for lymph node involvement, which may not be relevant to MPM. Therefore, in collaboration with IMIG, the International Association for the Study of Lung Cancer (IASLC) has decided to update the staging system for MPM by developing a large international database.

A study, published in the November 2012 issue of the IASLC'S Journal of Thoracic Oncology, reports the current staging system by and large appropriately distinguishes among T and N categories and overall stages but also highlights areas for potential revision.

The study looked at 3,101 patients from 15 centers in four continents. The current data still represents mainly surgically treated patients. The authors report that current T descriptors are qualitative and most applicable to pathological staging. Possibly in the future, volumetric tumor measurement could enhance the current T descriptors.

In addition, the data demonstrate a difference in survival for node-negative versus node-positive patients. The difference between N1 and N2 disease is less clear, suggesting that additional study of the extent of lymph node involvement might yield improvements in the N-classification factor.

And finally the authors suggest that staging groups, especially for stages I and II disease, need to be reassessed. In the future, they say, "the addition of a larger group of patients with more advanced disease, staged clinically and managed nonsurgically may help determine whether stages III and IV should be classified into a and b subcategories."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our asbestos / mesothelioma section for the latest news on this subject. The lead author of this work is IASLC member Dr. Valerie Rusch (USA). Co-authors include IASLC members Dorothy Giroux (USA), Catherine Kennedy (Australia), Dr. Erico Ruffini (Italy), Dr. David Rice (USA), Dr. Harvey Pass (USA), Dr. Hisao Asamura (Japan), Dr. John Edwards (U.K.) and Dr. Walter Weder (Switzerland).

International Association for the Study of Lung Cancer

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

International Association for the Study of Lung Ca. "First Analysis Of IASLC Malignant Pleural Mesothelioma Database." Medical News Today. MediLexicon, Intl., 17 Oct. 2012. Web.
29 May. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'First Analysis Of IASLC Malignant Pleural Mesothelioma Database'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here